NO990855L - Substituerte sykliske amin-metallprotease-inhibitorer - Google Patents

Substituerte sykliske amin-metallprotease-inhibitorer

Info

Publication number
NO990855L
NO990855L NO990855A NO990855A NO990855L NO 990855 L NO990855 L NO 990855L NO 990855 A NO990855 A NO 990855A NO 990855 A NO990855 A NO 990855A NO 990855 L NO990855 L NO 990855L
Authority
NO
Norway
Prior art keywords
protease inhibitors
cyclic amine
substituted cyclic
metal protease
amine metal
Prior art date
Application number
NO990855A
Other languages
English (en)
Other versions
NO990855D0 (no
NO315371B1 (no
Inventor
Michael George Natchus
Biswanath De
Stanislaw Pikul
Neil Gregory Almstead
Roger Gunnard Bookland
Yetunde Olabisi Taiwo
Menyan Cheng
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO990855D0 publication Critical patent/NO990855D0/no
Publication of NO990855L publication Critical patent/NO990855L/no
Publication of NO315371B1 publication Critical patent/NO315371B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
NO19990855A 1996-08-28 1999-02-23 Substituerte sykliske amin-metallprotease-inhibitorer NO315371B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2484296P 1996-08-28 1996-08-28
PCT/US1997/014555 WO1998008815A1 (en) 1996-08-28 1997-08-22 Substituted cyclic amine metalloprotease inhibitors

Publications (3)

Publication Number Publication Date
NO990855D0 NO990855D0 (no) 1999-02-23
NO990855L true NO990855L (no) 1999-04-23
NO315371B1 NO315371B1 (no) 2003-08-25

Family

ID=21822685

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990855A NO315371B1 (no) 1996-08-28 1999-02-23 Substituerte sykliske amin-metallprotease-inhibitorer

Country Status (30)

Country Link
US (6) US6417219B1 (no)
EP (1) EP0927161B1 (no)
JP (2) JP3541043B2 (no)
KR (1) KR100323272B1 (no)
CN (1) CN1232451A (no)
AT (1) ATE226193T1 (no)
AU (1) AU741893B2 (no)
BR (1) BR9713465A (no)
CA (1) CA2263928A1 (no)
CO (1) CO4900036A1 (no)
CZ (1) CZ63199A3 (no)
DE (1) DE69716449T2 (no)
DK (1) DK0927161T3 (no)
ES (1) ES2201318T3 (no)
HK (1) HK1020962A1 (no)
HU (1) HUP0000478A3 (no)
ID (1) ID18143A (no)
IL (1) IL128666A (no)
MY (1) MY116959A (no)
NO (1) NO315371B1 (no)
NZ (1) NZ334256A (no)
PE (1) PE109098A1 (no)
PL (1) PL331802A1 (no)
PT (1) PT927161E (no)
RU (1) RU2221782C2 (no)
SK (1) SK25099A3 (no)
TR (1) TR199900431T2 (no)
TW (1) TWI232218B (no)
WO (1) WO1998008815A1 (no)
ZA (1) ZA977698B (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE234291T1 (de) * 1995-12-08 2003-03-15 Agouron Pharma Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
PL331802A1 (en) * 1996-08-28 1999-08-02 Procter & Gamble Substituted cyclic amines as metaloprotease inhibitors
US6872742B2 (en) * 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
BR9810841A (pt) 1997-07-31 2001-07-10 Procter & Gamble Inibidores de metaloprotease alicìclicos
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
NZ505968A (en) 1998-02-04 2003-03-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1077978A1 (en) 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
BR9914196A (pt) * 1998-09-30 2001-06-19 Procter & Gamble Processo de tratamento da perda de cabelo
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6197770B1 (en) 1999-03-03 2001-03-06 The Procter & Gamble Co. Alkenyl- and alkynl-containing metalloprotease inhibitors
BR0009244A (pt) 1999-03-03 2002-04-16 Procter & Gamble Inibidores de metaloprotease di-hétero substituìdos
AU3196100A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
WO2001010837A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent sulfonamides
WO2001010838A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent compounds
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
AU2001250849A1 (en) * 2000-03-17 2001-10-03 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
KR100372757B1 (ko) * 2000-04-07 2003-02-17 삼성전자주식회사 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
JP4754155B2 (ja) 2000-06-30 2011-08-24 ザ プロクター アンド ギャンブル カンパニー 全身の健康の増進
JP4068452B2 (ja) 2000-07-19 2008-03-26 エフ．ホフマン−ラ ロシュ アーゲー エンドセリン変換酵素阻害剤としてのピロリジン誘導体
MXPA03000368A (es) * 2000-07-19 2004-09-13 Hoffmann La Roche Derivados de pirrolidina como inhibidores de metalproteasa.
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4825375B2 (ja) 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
EP1440057A1 (en) 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US7176217B2 (en) 2001-11-13 2007-02-13 Shiseido Co., Ltd. Azabicyclo compound matrix metalloprotease inhibitor and skin preparation
WO2003059265A2 (en) * 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US20070059381A1 (en) * 2003-06-20 2007-03-15 Barker Ronnie C Treatment of amd with combination of ingredients
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
KR101178747B1 (ko) 2004-09-30 2012-09-03 다케다 야쿠힌 고교 가부시키가이샤 프로톤 펌프 저해제
CA2598365A1 (en) * 2005-02-18 2006-11-16 Innodia Inc. Analogs of 4-hydroxyisoleucine and uses thereof
US7977488B2 (en) 2005-08-30 2011-07-12 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
SG170767A1 (en) 2005-12-23 2011-05-30 Zealand Pharma As Modified lysine-mimetic compounds
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
RS52872B (en) 2008-08-27 2013-12-31 Takeda Pharmaceutical Company Limited PIRAL UNITS
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
KR20140072894A (ko) * 2011-10-04 2014-06-13 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 신규의 세포사멸 유도 화합물
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
BR112019005416A2 (pt) 2016-09-20 2019-06-18 Glaxosmithkline Ip No 2 Ltd antagonistas de trpv4
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
JP6989864B2 (ja) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954158A (en) * 1983-08-16 1990-09-04 University Of Georgia Research Foundation, Inc. 2,3-methanoproline
ZA877471B (en) * 1986-10-08 1988-04-05 Bristol-Myers Company 1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acid antibacterial agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
MX9708026A (es) * 1995-04-20 1997-11-29 Pfizer Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos.
KR100266467B1 (ko) * 1995-09-27 2000-10-02 우에노 도시오 설폰아미드 유도체
ATE234291T1 (de) * 1995-12-08 2003-03-15 Agouron Pharma Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
PL331802A1 (en) * 1996-08-28 1999-08-02 Procter & Gamble Substituted cyclic amines as metaloprotease inhibitors
US6376506B1 (en) * 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6261775B1 (en) * 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma

Also Published As

Publication number Publication date
JP3541043B2 (ja) 2004-07-07
NO990855D0 (no) 1999-02-23
IL128666A0 (en) 2000-01-31
DE69716449T2 (de) 2003-08-07
US20050154019A1 (en) 2005-07-14
JP2000516955A (ja) 2000-12-19
PT927161E (pt) 2003-12-31
ZA977698B (en) 1998-02-23
AU741893B2 (en) 2001-12-13
PE109098A1 (es) 1999-02-19
CA2263928A1 (en) 1998-03-05
MY116959A (en) 2004-04-30
TWI232218B (en) 2005-05-11
EP0927161A1 (en) 1999-07-07
NZ334256A (en) 2000-11-24
DK0927161T3 (da) 2003-02-17
CN1232451A (zh) 1999-10-20
US20030191163A1 (en) 2003-10-09
PL331802A1 (en) 1999-08-02
HUP0000478A2 (hu) 2000-09-28
US20050101567A1 (en) 2005-05-12
US6417219B1 (en) 2002-07-09
US6858628B2 (en) 2005-02-22
ES2201318T3 (es) 2004-03-16
ID18143A (id) 1998-03-05
SK25099A3 (en) 2000-02-14
KR20000035922A (ko) 2000-06-26
WO1998008815A1 (en) 1998-03-05
HK1020962A1 (en) 2000-05-26
EP0927161B1 (en) 2002-10-16
BR9713465A (pt) 2000-03-28
TR199900431T2 (xx) 1999-04-21
KR100323272B1 (ko) 2002-02-06
US6569855B2 (en) 2003-05-27
NO315371B1 (no) 2003-08-25
JP2004115531A (ja) 2004-04-15
CZ63199A3 (cs) 1999-08-11
RU2221782C2 (ru) 2004-01-20
IL128666A (en) 2005-09-25
DE69716449D1 (de) 2002-11-21
HUP0000478A3 (en) 2000-10-30
ATE226193T1 (de) 2002-11-15
US20020072517A1 (en) 2002-06-13
US20020061877A1 (en) 2002-05-23
CO4900036A1 (es) 2000-03-27
AU4074197A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
NO990855D0 (no) Substituerte sykliske amin-metallprotease-inhibitorer
PT966465E (pt) Inibidores do enzima imfdh
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
EA200100867A1 (ru) Сульфаматогидроксамовая кислота как ингибитор металлопротеаз
BR0013200A (pt) Compostos derivados de heterobiciclos contendo nitrogênio, composições farmacêuticas, método de tratamento ou prevenção de uma disfunção tromboembólica e uso dos compostos
BR9713182A (pt) Amidas de ácido fosfìnico como inibidores de metalo protease de matriz
FI942423A0 (fi) Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
NO983688L (no) Serin-protease-inhibitorer
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
ATE170868T1 (de) Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
NO990896L (no) Bidentate metalloproteaseinhibitorer
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
DE60329326D1 (de) Tace inhibitoren
TR200003065T2 (tr) Nöraminidazların inhibitörleri olarak pirolidinler.
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos
ATE253050T1 (de) Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
MX9704968A (es) Inhibidores que contienen acido hidroxamico de metaloproteasas de matriz.
WO2001070682A3 (en) Carbocyclic side chain containing metalloprotease inhibitors
TH52371A (th) สารยับยั้งบีตาไดซับสทิทิวเทด-เมแทลโลโปรทีเอส
BG103044A (en) 7-bromo- and 7,7-dibromo-cepham and -cephem derivatives